News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
IVRN make a move on nice volume for this low floater IVRN Security Details
Share Structure
Market Cap Market Cap
125,215
03/28/2024
Authorized Shares
500,000,000
03/21/2024
Outstanding Shares
3,794,397
03/21/2024
Restricted
1,798,572
03/21/2024
Unrestricted
1,995,825
03/21/2024
Held at DTC
1,811,234
03/21/2024
IVRN looking good here for a real move at anytime
I meant IVRN can run like NILA did but we are a SEC filing company and I dont expect unbelievable PRs from this one, just great updates, so no luck needed just timing, load the quite
this one is filing SEC so I dont think we get a P&D but some real updates here, sold the other way to early but who knew so many would jump on after it was up 500% already IVRN insiders took .25s so should be easy til there 4 sure Item 3.02 Unregistered Sales of Equity Securities.
Pursuant to the Purchase Agreement, the Company sold an aggregate of 400,000 shares of common stock and 400,000 warrants to purchase shares of Common Stock exercisable at $0.50 per share for gross proceeds of $100,000. All of the shares and warrants described in this Current Report on Form 8-K are being offered and issued to an accredited investor in reliance upon exemptions from the registration requirements under Section 4(a)(2) under the Securities Act of 1933, as amended (“Securities Act”), and Rule 506 of Regulation D promulgated thereunder.
Item 5.02, Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers;
On February 23, 2024, the Company issued to certain executive officers an aggregate of 186,048 shares of common stock in lieu of accrued salary at a rate of $0.25 per share for amounts owed and an aggregate of 213,952 shares for payment of directors’ fees owed.. In addition, the Company converted a promissory note in the amount of $43,091 owed to the Company’s Chief Executive Officer, Michael Yurkowsky, into the private placement in exchange for 172,364 shares of common stock and 172,364 warrants which is the same price paid by the accredited investor..
https://www.otcmarkets.com/filing/html?id=17321282&guid=aKd-knf_5YvuB3h
maybe we can repeat NILA here IVRN has an even better SS
IVRN starting a position here IVRN Security Details
Share Structure
Market Cap Market Cap
106,243
03/25/2024
Authorized Shares
500,000,000
03/21/2024
Outstanding Shares
3,794,397
03/21/2024
Restricted
1,798,572
03/21/2024
Unrestricted
1,995,825
03/21/2024
Held at DTC
1,811,234
03/21/2024
IVRN over 300k traded on tiny 1.1m floater, could see dollars this week
yeap news tiny MC SS IVRN Innoveren Scientific Announces 510(k) Submission for SkinDisc(TM) Lite
First Commercial Product Submission from Company's Robust Regenerative Medicine-Based Pipeline
CINCINNATI, OH / ACCESSWIRE / March 6, 2024 / Innoveren Scientific Inc. (OTCQB:IVRN) ("Innoveren" or the "Company"), a life science company focused on becoming a leading biotech incubator, announced today that it has submitted a 510(k) premarket filing to the U.S. Federal Food and Drug Administration (FDA) for its SkinDiscTM Lite product.
SkinDiscTM Lite provides an active and protein-rich cellular matrix that is essential for structural support and cellular attachment during the wound-healing process that can be administered in an outpatient setting. The product maintains complete wound contact and depth fill during the healing process, resulting in rapid growth of the host tissue. SkinDiscTM Lite utilizes autologous platelet-rich plasma (PRP) and platelet poor plasma concentrate, from the patient's own body, helping to mitigate any potential rejection of the product.
"The FDA submission for SkinDiscTM Lite represents a significant milestone for Innoveren Scientific in our journey to advance our new medical technologies in areas of unmet need across multiple indications," said Michael Yurkowsky, Innoveren Scientific's Chief Executive Officer. "With the use of PRP, which already has predicates in wound care cleared by the FDA, we are hopeful we will also receive clearance for SkinDiscTM Lite, allowing us to continue to advance our pipeline and submit a 510(k) submission for SkinDiscTM Ultra in the coming quarters."
Innoveren Scientific is prepared to submit a second 510(k) De Novo submission for SkinDiscTM Ultra should clearance be received for SkinDiscTM Lite. SkinDiscTM Ultra is an operating room-only product for limb salvage that utilizes bone marrow aspirate (BMA).
The Company is also making progress on advancing its BreatheEasy product, a medical device that helps patients struggling with chronic obstructive pulmonary disease (COPD), as well as other closely related diseases such as chronic bronchitis and emphysema. The Company is on track for a 510(k) De Novo submission later this year once additional clinical work has been completed.
About Innoveren Scientific Inc.
Innoveren Scientific Inc., formerly known as H-CYTE, Inc. is a life science and biotech incubator company, focused on advancing new technologies in areas of unmet need across multiple indications, with the ultimate goal of improving patient lives. The company invests in and fosters innovative technologies that are supported by a strong scientific foundation, which have relatively short timelines and low costs to achieve meaningful value inflection points. For more information about Innoveren, please visit www.InnoverenScientific.com. IVRN Security Details
Share Structure
Market Cap Market Cap
85,289
03/05/2024
Authorized Shares
500,000,000
03/04/2024
Outstanding Shares
2,584,518
03/04/2024
Restricted
1,279,698
03/04/2024
Unrestricted
1,304,820
03/04/2024
Held at DTC
1,120,229
03/04/2024
